The demand for drug eruptions treatment in Japan is projected to grow from USD 240.7 million in 2026 to USD 407.4 million by 2036, at a CAGR of 4.9%. Corticosteroids will dominate with a 28.0% market share, while oral will lead the route of administration segment with a 40.0% share.